Pilot and Feasibility Studies (Jan 2025)

Feasibility and preliminary efficacy of a physical activity intervention in adults with lymphoma undergoing treatment

  • Juliana V. Costa,
  • Alexander R. Lucas,
  • Shannon L. Mihalko,
  • Peter H. Brubaker,
  • Alexandra Marshall,
  • Brianna Leitzelar,
  • Brianna R. Wolle,
  • Samuel Norton,
  • R. Lee Franco,
  • Jeremy Via,
  • Victor Yazbeck,
  • Rakhee Vaidya,
  • Mary Beth Seegars,
  • Ralph D’Agostino,
  • Lynne Wagner,
  • W. Gregory Hundley

DOI
https://doi.org/10.1186/s40814-024-01580-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background To determine the feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention (PAI) for lymphoma patients undergoing chemotherapy. Methods Patients newly diagnosed with lymphoma (non-Hodgkin (NHL) or Hodgkin (HL)) were randomized into the PAI or healthy living intervention (HLI) control (2:1). Feasibility was assessed by examining accrual, adherence, and retention rates. Participants completed assessments of exercise capacity (VO2 peak and 6-min walk distance (6MWD)), objective and self-reported levels of physical activity, MRI-derived cardiovascular functioning (Left Ventricular Ejection Fraction [LVEF], stroke volume, and cardiac output), and self-reported health-related and disease-specific quality of life and self-efficacy for exercise at baseline, 3, and 6 months. Results One hundred and forty-five individuals were screened with 23 of 84 eligible patients agreeing to participate (27%). Three participants withdrew before baseline testing. Out of the 20 participants randomized to the PAI (n = 13) and HLI groups (n = 7), 18 completed the intervention resulting in an overall retention rate of 78%. The adherence rates to the PAI and HLI were 85% and 87%, respectively. One non-serious adverse event was registered. VO2 peak ranged from 15.5–28.0 ml/kg/min at baseline and participants in both groups improved by 6 months. Physical activity levels and cardiovascular function were reduced prior to treatment but did not deteriorate further. Conclusions Implementing a tailored PAI in adults with lymphoma during active treatment is feasible, was well received by participants and shows preliminary efficacy for limiting a decline in function during treatment. Potential Implications for Cancer Survivors: Physical activity may be beneficial for improving exercise capacity and health-related quality of life in patients undergoing chemotherapy. Trial registration #NCT01719562 ClinicalTrials.gov. Registered July 2, 2019—retrospectively registered.

Keywords